Why interleukin-10 supplementation does not work in Crohn's disease patients

World Journal of Gastroenterology

Volumn 19, Issue 25, 2013, Pages 3931-3941

  Marlow, Gareth J ^a   van Gent, Dominique ^a   Ferguson, Lynnette R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Crohn's disease; Inflammatory bowel disease; Interleukin 10; Recombinant human interleukin 10

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MESALAZINE; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT GROWTH FACTOR; RECOMBINANT INTERLEUKIN 10; RHUIL 10; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC ARTHRITIS; CROHN DISEASE; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; ELISA KIT; ENTERITIS; GENE MUTATION; GENETIC VARIABILITY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REMISSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84880076939     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i25.3931     Document Type: Article

References (131)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
2. Paul G, Khare V, Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J Clin Invest 2012; 42: 95-109 [PMID: 21631466 DOI: 10.1111/j.1365-2362.2011.02552.x]
3. Cooney R, Jewell D. The genetic basis of inflammatory bowel disease. Dig Dis 2009; 27: 428-442 [PMID: 19897957 DOI: 10.1159/000234909]
4. Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci 2011; 1246: 102-107 [PMID: 22236434 DOI: 10.1111/ j.1749-6632.2011.06339.x]
5. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012; 380: 1590-1605 [PMID: 22914295 DOI: 10.1016/ S0140-6736(12)60026-9]
6. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8: 458-466 [PMID: 18500230 DOI: 10.1038/nri2340]
7. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, Bradfield JP, Walters TD, Sleiman P, Kim CE, Muise A, Wang K, Glessner JT, Saeed S, Zhang H, Frackelton EC, Hou C, Flory JH, Otieno G, Chiavacci RM, Grundmeier R, Castro M, Latiano A, Dallapiccola B, Stempak J, Abrams DJ, Taylor K, McGovern D, Silber G, Wrobel I, Quiros A, Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmuda MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwillam R, Tremelling M, Delukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ, Heyman MB, Ferry GD, Kirschner B, Lee J, Essers J, Grand R, Stephens M, Levine A, Piccoli D, Van Limbergen J, Cucchiara S, Monos DS, Guthery SL, Denson L, Wilson DC, Grant SF, Daly M, Silverberg MS, Satsangi J, Hakonarson H. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009; 41: 1335-1340 [PMID: 19915574 DOI: 10.1038/ng.489]
8. Reiff C, Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol 2010; 300: 25-33 [PMID: 19800289]
9. Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 2007; 115: 1-11 [PMID: 17137666 DOI: 10.1016/j.ijfoodmicro.2006.10.006]
10. Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31: 1-20 [PMID: 12122726]
11. Shanahan F. Probiotics in inflammatory bowel disease-- therapeutic rationale and role. Adv Drug Deliv Rev 2004; 56: 809-818 [PMID: 15063591 DOI: 10.1016/j.addr.2003.11.003]
12. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D' Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-124 [PMID: 23128233 DOI: 10.1038/nature11582]
13. Franke A, McGovern DP, Barrett JC, Wang K, Radford- Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M. Genome-wide metaanalysis increases to 71 the number of confirmed Crohn' s disease susceptibility loci. Nat Genet 2010; 42: 1118-1125 [PMID: 21102463 DOI: 10.1038/ng.717]
14. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011; 60: 1739-1753 [PMID: 21300624 DOI: 10.1136/gut.2009.199679]
15. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008; 40: 1319-1323 [PMID: 18836448 DOI: 10.1038/ng.221]
16. Aithal GP, Craggs A, Day CP, Welfare M, Daly AK, Mansfield JC, Hudson M. Role of polymorphisms in the interleukin- 10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Dig Dis Sci 2001; 46: 1520-1525 [PMID: 11478505]
17. Amre DK, Mack DR, Morgan K, Israel D, Lambrette P, Costea I, Krupoves A, Fegury H, Dong J, Grimard G, Deslandres C, Levy E, Seidman EG. Interleukin 10 (IL-10) gene variants and susceptibility for paediatric onset Crohn' s disease. Aliment Pharmacol Ther 2009; 29: 1025-1031 [PMID: 19210299 DOI: 10.1111/j.1365-2036.2009.03953.x]
18. Wang AH, Lam WJ, Han DY, Ding Y, Hu R, Fraser AG, Ferguson LR, Morgan AR. The effect of IL-10 genetic variation and interleukin 10 serum levels on Crohn's disease susceptibility in a New Zealand population. Hum Immunol 2011; 72: 431-435 [PMID: 21354456 DOI: 10.1016/ j.humimm.2011.02.014]
19. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-- review of a new approach. Pharmacol Rev 2003; 55: 241-269 [PMID: 12773629 DOI: 10.1124/pr.55.2.4]
20. Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10- based therapy for inflammatory bowel disease. Expert Opin Biol Ther 2003; 3: 725-731 [PMID: 12880373 DOI: 10.1517/147 12598.3.5.725]
21. Buruiana FE, Solà I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; (11): CD005109 [PMID: 21069683 DOI: 10.1002/14651858.CD005109.pub3]
22. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K, Melani L, Cohard M. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001; 49: 42-46 [PMID: 11413109]
23. Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Coopera-tive Study Group. Gastroenterology 2000; 119: 1473-1482 [PMID: 11113068]
24. Herfarth H, Schölmerich J. IL-10 therapy in Crohn's disease: at the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10. Gut 2002; 50: 146-147 [PMID: 11788549]
25. Lindsay JO, Hodgson HJ. Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease? Aliment Pharmacol Ther 2001; 15: 1709-1716 [PMID: 11683684]
26. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, Jacyna M, Lashner BA, Gangl A, Rutgeerts P, Isaacs K, van Deventer SJ, Koningsberger JC, Cohard M, LeBeaut A, Hanauer SB. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000; 119: 1461-1472 [PMID: 11113067]
27. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJ, Schreiber S, Gregor M, Ludwiczek O, Rutgeerts P, Gasche C, Koningsberger JC, Abreu L, Kuhn I, Cohard M, LeBeaut A, Grint P, Weiss G. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002; 50: 191-195 [PMID: 11788558 DOI: 10.1136/gut.50.2.191]
28. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113: 383-389 [PMID: 9247454]
29. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-2095 [PMID: 2531194]
30. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M. The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004; 15: 61-76 [PMID: 14746814]
31. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure 1995; 3: 591-601 [PMID: 8590020]
32. Ho AS, Liu Y, Khan TA, Hsu DH, Bazan JF, Moore KW. A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci USA 1993; 90: 11267-11271 [PMID: 8248239]
33. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994; 56: 1-26 [PMID: 8073945]
34. de Moreno de Leblanc A, Del Carmen S, Zurita-Turk M, Santos Rocha C, van de Guchte M, Azevedo V, Miyoshi A, Leblanc JG. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol 2011; 2011: 892971 [PMID: 21991534 DOI: 10.5402/2011/892971]
35. Schottelius AJ, Baldwin AS. A role for transcription factor NF-kappa B in intestinal inflammation. Int J Colorectal Dis 1999; 14: 18-28 [PMID: 10207726]
36. Dijkstra G, Moshage H, Jansen PL. Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand J Gastroenterol Suppl 2002; (236): 37-41 [PMID: 12408502]
37. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS. Interleukin- 10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999; 274: 31868-31874 [PMID: 10542212]
38. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995; 270: 9558-9563 [PMID: 7721885]
39. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol 2004; 135: 64-73 [PMID: 14678266]
40. Koppelman B, Neefjes JJ, de Vries JE, de Waal Malefyt R. Interleukin-10 down-regulates MHC class II alphabeta peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 1997; 7: 861-871 [PMID: 9430231]
41. Willems F, Marchant A, Delville JP, Gérard C, Delvaux A, Velu T, de Boer M, Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24: 1007-1009 [PMID: 7512027 DOI: 10.1002/eji.1830240435]
42. Chan LL, Cheung BK, Li JC, Lau AS. A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-gammainduced MHC class II molecule on primary human blood macrophages. J Leukoc Biol 2010; 88: 303-311 [PMID: 20356901 DOI: 10.1189/jlb.1009659]
43. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224-1234 [PMID: 7687627]
44. Buelens C, Willems F, Delvaux A, Piérard G, Delville JP, Velu T, Goldman M. Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol 1995; 25: 2668-2672 [PMID: 7589143 DOI: 10.1002/eji.1830250940]
45. McBride JM, Jung T, de Vries JE, Aversa G. IL-10 alters DC function via modulation of cell surface molecules resulting in impaired T-cell responses. Cell Immunol 2002; 215: 162-172 [PMID: 12202153]
46. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220 [PMID: 1940799]
47. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-360 [PMID: 8419468]
48. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-3822 [PMID: 1940369]
49. Galbas T, Steimle V, Lapointe R, Ishido S, Thibodeau J. MARCH1 down-regulation in IL-10-activated B cells increases MHC class II expression. Cytokine 2012; 59: 27-30 [PMID: 22503116 DOI: 10.1016/j.cyto.2012.03.015]
50. Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992; 89: 1890-1893 [PMID: 1371884]
51. Glocker EO, Frede N, Perro M, Sebire N, Elawad M, Shah N, Grimbacher B. Infant colitis--it's in the genes. Lancet 2010; 376: 1272 [PMID: 20934598 DOI: 10.1016/ S0140-6736(10)61008-2]
52. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, Buderus S, Snapper SB, Grimbacher B, Klein C. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033-2045 [PMID: 19890111 DOI: 10.1056/NEJMoa0907206]
53. Donnelly RP, Dickensheets H, Finbloom DS. The interleukin- 10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 1999; 19: 563-573 [PMID: 10433356 DOI: 10.1089/107999099313695]
54. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765 [PMID: 11244051 DOI: 10.1146/annurev. immunol.19.1.683]
55. Williams LM, Ricchetti G, Sarma U, Smallie T, Foxwell BM. Interleukin-10 suppression of myeloid cell activation- -a continuing puzzle. Immunology 2004; 113: 281-292 [PMID: 15500614 DOI: 10.1111/j.1365-2567.2004.01988.x]
56. Li Y, de Haar C, Peppelenbosch MP, van der Woude CJ. New insights into the role of STAT3 in IBD. Inflamm Bowel Dis 2012; 18: 1177-1183 [PMID: 21994179 DOI: 10.1002/ ibd.21884]
57. Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, Schütz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schürmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6: 583-588 [PMID: 10802717 DOI: 10.1038/75068]
58. Ohta N, Hiroi T, Kweon MN, Kinoshita N, Jang MH, Mashimo T, Miyazaki J, Kiyono H. IL-15-dependent activation-induced cell death-resistant Th1 type CD8 alpha beta+NK1.1+ T cells for the development of small intestinal inflammation. J Immunol 2002; 169: 460-468 [PMID: 12077277]
59. Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology 2002; 122: 2011-2025 [PMID: 12055606]
60. Fitzpatrick LR. Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis. Int J Inflam 2012; 2012: 389404 [PMID: 22506136 DOI: 10.1155/2012/389404]
61. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB, Varilek GW, Buchman AL, Rodgers VD, Salzberg B, Cai B, Loewy J, DeBruin MF, Rogge H, Shapiro M, Schwertschlag US. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117: 58-64 [PMID: 10381910]
62. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534-544 [PMID: 18172556 DOI: 10.1172/JCI33194]
63. Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001; 120: 925-937 [PMID: 11231946]
64. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004; 172: 567-576 [PMID: 14688368]
65. Sugimoto K. Role of STAT3 in inflammatory bowel disease. World J Gastroenterol 2008; 14: 5110-5114 [PMID: 18777586]
66. Hruz P, Dann SM, Eckmann L. STAT3 and its activators in intestinal defense and mucosal homeostasis. Curr Opin Gastroenterol 2010; 26: 109-115 [PMID: 20040863 DOI: 10.1097/ MOG.0b013e3283365279]
67. El Kasmi KC, Holst J, Coffre M, Mielke L, de Pauw A, Lhocine N, Smith AM, Rutschman R, Kaushal D, Shen Y, Suda T, Donnelly RP, Myers MG, Alexander W, Vignali DA, Watowich SS, Ernst M, Hilton DJ, Murray PJ. General nature of the STAT3-activated anti-inflammatory response. J Immunol 2006; 177: 7880-7888 [PMID: 17114459]
68. Murray PJ. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol 2006; 6: 379-386 [PMID: 16713356 DOI: 10.1016/j.coph.2006.01.010]
69. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, Rossaint R, Heinrich PC, Müller-Newen G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 2003; 170: 3263-3272 [PMID: 12626585]
70. Lovato P, Brender C, Agnholt J, Kelsen J, Kaltoft K, Svejgaard A, Eriksen KW, Woetmann A, Ødum N. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J Biol Chem 2003; 278: 16777-16781 [PMID: 12615922 DOI: 10.1074/jbc.M207999200]
71. Mudter J, Weigmann B, Bartsch B, Kiesslich R, Strand D, Galle PR, Lehr HA, Schmidt J, Neurath MF. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am J Gastroenterol 2005; 100: 64-72 [PMID: 15654782 DOI: 10.1111/ j.1572-0241.2005.40615.x]
72. Musso A, Dentelli P, Carlino A, Chiusa L, Repici A, Sturm A, Fiocchi C, Rizzetto M, Pegoraro L, Sategna-Guidetti C, Brizzi MF. Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 2005; 11: 91-98 [PMID: 15677901]
73. Andersen V, Ernst A, Christensen J, Ostergaard M, Jacobsen B, Tjonneland A, Krarup H, Vogel U. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish casecontrol study. BMC Medical Genetics 2010; 11: 82 [DOI: 10.1186/1471-2350-11-82]
74. Sanchez R, Levy E, Costea F, Sinnett D. IL-10 and TNFalpha promoter haplotypes are associated with childhood Crohn's disease location. World J Gastroenterol 2009; 15: 3776-3782 [PMID: 19673019]
75. Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D, Hugot JP, Daussy C, Verkarre V, Pigneur B, Fischer A, Klein C, Cerf-Bensussan N, Ruemmele FM. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 2011; 106: 1544-1555 [PMID: 21519361 DOI: 10.1038/ajg.2011.112]
76. Ishizuka K, Sugimura K, Homma T, Matsuzawa J, Mochizuki T, Kobayashi M, Suzuki K, Otsuka K, Tashiro K, Yamaguchi O, Asakura H. Influence of interleukin-10 on the interleukin-1 receptor antagonist/interleukin-1 beta ratio in the colonic mucosa of ulcerative colitis. Digestion 2001; 63 Suppl 1: 22-27 [PMID: 11173905]
77. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin- 10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274 [PMID: 8402911 DOI: 10.1016/0092-8674(9 3)80068-P]
78. Correa I, Veny M, Esteller M, Piqué JM, Yagüe J, Panés J, Salas A. Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol 2009; 85: 896-903 [PMID: 19237638 DOI: 10.1189/jlb.1108698]
79. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 1434-1444 [PMID: 7729636]
80. Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J Clin Immunol 2000; 20: 362-370 [PMID: 11051278]
81. Nielsen OH, Køppen T, Rüdiger N, Horn T, Eriksen J, Kirman I. Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci 1996; 41: 1786-1793 [PMID: 8794795]
82. Kucharzik T, Stoll R, Lügering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 100: 452-456 [PMID: 7774055]
83. Meresse B, Rutgeerts P, Malchow H, Dubucquoi S, Dessaint JP, Cohard M, Colombel JF, Desreumaux P. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut 2002; 50: 25-28 [PMID: 11772962]
84. Melgar S, Yeung MM, Bas A, Forsberg G, Suhr O, Oberg A, Hammarstrom S, Danielsson A, Hammarstrom ML. Overexpression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis. Clin Exp Immunol 2003; 134: 127-137 [PMID: 12974765]
85. Mitsuyama K, Tomiyasu N, Takaki K, Masuda J, Yamasaki H, Kuwaki K, Takeda T, Kitazaki S, Tsuruta O, Sata M. Interleukin- 10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm 2006; 2006: 26875 [PMID: 17392581 DOI: 10.1155/MI/2006/26875]
86. Ljuca F, Gegic A, Salkic NN, Pavlovic-Calic N. Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease. Dig Dis Sci 2010; 55: 2316-2326 [PMID: 19834804 DOI: 10.1007/s10620-009-1016-9]
87. Santaolalla R, Mañé J, Pedrosa E, Lorén V, Fernández- Bañares F, Mallolas J, Carrasco A, Salas A, Rosinach M, Forné M, Espinós JC, Loras C, Donovan M, Puig P, Mañosa M, Gassull MA, Viver JM, Esteve M. Apoptosis resistance of mucosal lymphocytes and IL-10 deficiency in patients with steroid-refractory Crohn's disease. Inflamm Bowel Dis 2011; 17: 1490-1500 [PMID: 21674705 DOI: 10.1002/ibd.21507]
88. Borska L, Andrys C, Krejsek J, Hamakova K, Kremlacek J, Ettler K, Fiala Z. Serum levels of the pro-inflammatory cytokine interleukin-12 and the anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimen. Int J Dermatol 2008; 47: 800-805 [PMID: 18717859 DOI: 10.1111/j.1365-4632.2008.03677.x]
89. Ying B, Shi Y, Pan X, Song X, Huang Z, Niu Q, Cai B, Wang L. Association of polymorphisms in the human IL-10 and IL-18 genes with rheumatoid arthritis. Mol Biol Rep 2011; 38: 379-385 [PMID: 20424918 DOI: 10.1007/s11033-010-0119-x]
90. Szkaradkiewicz A, Marciniak R, Chudzicka-Strugała I, Wasilewska A, Drews M, Majewski P, Karpiński T, Zwoździak B. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp (Warsz) 2009; 57: 291-294 [PMID: 19578817 DOI: 10.1007/s00005-009-0031-z]
91. Roda G, Marocchi M, Sartini A, Roda E. Cytokine Networks in Ulcerative Colitis. Ulcers 2011; 2011: 391787 [DOI: 10.1155/2011/391787]
92. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-4288 [PMID: 18666314]
93. Settin AA, Hassan HA, El-Baz RA, Hassan TA. Association of cytokine gene polymorphisms with psoriasis in cases from the nile delta of egypt. Indian J Dermatol 2011; 56: 272-277 [PMID: 21772586]
94. Heiskanen M, Kähönen M, Hurme M, Lehtimäki T, Mononen N, Juonala M, Hutri-Kähönen N, Viikari J, Raitakari O, Hulkkonen J. Polymorphism in the IL10 promoter region and early markers of atherosclerosis: the Cardiovascular Risk in Young Finns Study. Atherosclerosis 2010; 208: 190-196 [PMID: 19700159 DOI: 10.1016/j.atherosclerosis.200 9.06.032]
95. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002; 62: 3369-3372 [PMID: 12067976]
96. Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 2003; 49: 1664-1667 [PMID: 14500594]
97. Stanczuk GA, Sibanda EN, Perrey C, Chirara M, Pravica V, Hutchinson IV, Tswana SA. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer 2001; 94: 792-794 [PMID: 11745479 DOI: 10.1002/ijc.1543]
98. Ni P, Xu H, Xue H, Lin B, Lu Y. A meta-analysis of interleukin- 10-1082 promoter polymorphism associated with gastric cancer risk. DNA Cell Biol 2012; 31: 582-591 [PMID: 22335769 DOI: 10.1089/dna.2011.1440]
99. Xue H, Lin B, An J, Zhu Y, Huang G. Interleukin-10-819 promoter polymorphism in association with gastric cancer risk. BMC Cancer 2012; 12: 102 [PMID: 22436502 DOI: 10.118 6/1471-2407-12-102]
100. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, Kruglyak L, Stein L, Hsie L, Topaloglou T, Hubbell E, Robinson E, Mittmann M, Morris MS, Shen N, Kilburn D, Rioux J, Nusbaum C, Rozen S, Hudson TJ, Lipshutz R, Chee M, Lander ES. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science 1998; 280: 1077-1082 [PMID: 9582121]
101. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465-9470 [PMID: 9689103]
102. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8 [PMID: 9043871]
103. Fowler EV, Eri R, Hume G, Johnstone S, Pandeya N, Lincoln D, Templeton D, Radford-Smith GL. TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease. J Med Genet 2005; 42: 523-528 [PMID: 15937090 DOI: 10.1136/jmg.2004.027425]
104. Fernandez L, Martinez A, Mendoza JL, Urcelay E, Fernandez- Arquero M, Garcia-Paredes J, Diaz-Rubio M, de la Concha EG. Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm Bowel Dis 2005; 11: 739-743 [PMID: 16043989]
105. Tedde A, Laura Putignano A, Bagnoli S, Congregati C, Milla M, Sorbi S, Genuardi M, Papi L. Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner. Scand J Gastroenterol 2008; 43: 712-718 [PMID: 18569989 DOI: 10.1080/00365520701885507]
106. Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, Mc- Mahon R, Whorwell PJ, Sinnott PJ, Hutchinson IV. Interleukin- 10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 1999; 54: 386-390 [PMID: 10551422]
107. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun 2000; 1: 185-190 [PMID: 11196710 DOI: 10.1038/ sj.gene.6363657]
108. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Höhler T. Differential regulation of interleukin-10 production by genetic and environmental factors--a twin study. Genes Immun 2002; 3: 407-413 [PMID: 12424622]
109. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42: 1101-1108 [PMID: 10366102 DOI: 10.1002/1529-0131(199906)42]
110. Looijer-van Langen MA, Dieleman LA. Prebiotics in chronic intestinal inflammation. Inflamm Bowel Dis 2009; 15: 454-462 [PMID: 18831524 DOI: 10.1002/ibd.20737]
111. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep 2011; 63: 629-642 [PMID: 21857074]
112. Ferguson LR, Philpott M, Dryland P. Nutrigenomics in the whole-genome scanning era: Crohn's disease as example. Cell Mol Life Sci 2007; 64: 3105-3118 [PMID: 17922230 DOI: 10.1007/s00018-007-7303-8]
113. Ferguson LR, Shelling AN, Browning BL, Huebner C, Petermann I. Genes, diet and inflammatory bowel disease. Mutat Res 2007; 622: 70-83 [PMID: 17628615 DOI: 10.1016/ j.mrfmmm.2007.05.011]
114. Triggs CM, Munday K, Hu R, Fraser AG, Gearry RB, Barclay ML, Ferguson LR. Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat Res 2010; 690: 123-138 [PMID: 20144628 DOI: 10.1016/ j.mrfmmm.2010.01.020]
115. Joachim G. Responses of people with inflammatory bowel disease to foods consumed. Gastroenterol Nurs 2000; 23: 160-167 [PMID: 11310083]
116. Jowett SL, Seal CJ, Pearce MS, Phillips E, Gregory W, Barton JR, Welfare MR. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004; 53: 1479-1484 [PMID: 15361498 DOI: 10.1136/ gut.2003.024828]
117. Jowett SL, Seal CJ, Phillips E, Gregory W, Barton JR, Welfare MR. Dietary beliefs of people with ulcerative colitis and their effect on relapse and nutrient intake. Clin Nutr 2004; 23: 161-170 [PMID: 15030955 DOI: 10.1016/ S0261-5614(03)00132-8]
118. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 2011; 106: 563-573 [PMID: 21468064 DOI: 10.1038/ajg.2011.44]
119. McHutchison JG, Giannelli G, Nyberg L, Blatt LM, Waite K, Mischkot P, Pianko S, Conrad A, Grint P. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J Interferon Cytokine Res 1999; 19: 1265-1270 [PMID: 10574619 DOI: 10.1089/107999099312939]
120. Rosenblum IY, Johnson RC, Schmahai TJ. Preclinical safety evaluation of recombinant human interleukin-10. Regul Toxicol Pharmacol 2002; 35: 56-71 [PMID: 11846636 DOI: 10.1006/rtph.2001.1504]
121. Barbara G, Xing Z, Hogaboam CM, Gauldie J, Collins SM. Interleukin 10 gene transfer prevents experimental colitis in rats. Gut 2000; 46: 344-349 [PMID: 10673295]
122. Duchmann R, Schmitt E, Knolle P, Meyer zum Büschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26: 934-938 [PMID: 8625991 DOI: 10.1002/eji.1830260432]
123. Grool TA, van Dullemen H, Meenan J, Koster F, ten Kate FJ, Lebeaut A, Tytgat GN, van Deventer SJ. Anti-inflammatory effect of interleukin-10 in rabbit immune complexinduced colitis. Scand J Gastroenterol 1998; 33: 754-758 [PMID: 9712241]
124. Ribbons KA, Thompson JH, Liu X, Pennline K, Clark DA, Miller MJ. Anti-inflammatory properties of interleukin-10 administration in hapten-induced colitis. Eur J Pharmacol 1997; 323: 245-254 [PMID: 9128846]
125. Sasaki M, Mathis JM, Jennings MH, Jordan P, Wang Y, Ando T, Joh T, Alexander JS. Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. J Inflamm (Lond) 2005; 2: 13 [PMID: 16259632 DOI: 10.1186/1476-9255-2-13]
126. Tomoyose M, Mitsuyama K, Ishida H, Toyonaga A, Tanikawa K. Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand J Gastroenterol 1998; 33: 435-440 [PMID: 9605267]
127. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352-1355 [PMID: 10958782]
128. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 754-759 [PMID: 16716759 DOI: 10.1016/ j.cgh.2006.03.028]
129. Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ. Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut 2003; 52: 363-369 [PMID: 12584217]
130. Nakase H, Okazaki K, Tabata Y, Ozeki M, Watanabe N, Ohana M, Uose S, Uchida K, Nishi T, Mastuura M, Tamaki H, Itoh T, Kawanami C, Chiba T. New cytokine delivery system using gelatin microspheres containing interleukin-10 for experimental inflammatory bowel disease. J Pharmacol Exp Ther 2002; 301: 59-65 [PMID: 11907157]
131. Herfarth HH, Böcker U, Janardhanam R, Sartor RB. Subtherapeutic corticosteroids potentiate the ability of interleukin 10 to prevent chronic inflammation in rats. Gastroenterology 1998; 115: 856-865 [PMID: 9753488]